BIOMAT Database Logo BIOMAT Database Logo

Fast genotypic detection of drug resistance mutations in the HIV-1 reverse transcriptase gene of treatment-naive patients. 1998

E Fontaine, and C Lambert, and J Servais, and D Ninove, and J M Plesséria, and T Staub, and V Arendt, and P Kirpach, and I Robert, and F Schneider, and R Hemmer, and J C Schmit
Laboratoire de Rétrovirologie, Centre de Recherche Public-Santé, Luxembourg.

OBJECTIVE This study was performed to assess the frequency of drug resistance mutations in treatment-naive HIV-1-infected patients. METHODS Frozen plasma samples from 135 treatment-naive HIV-infected adults were available from the first time the patients were seen for their infection in our center between 1992 and 1997. A rapid genotypic assay based on reverse DNA hybridization (LiPA HIV-1 RT, Murex, London, U.K.) was used to study substitutions at reverse transcriptase (RT) codons 41, 69, 70, 74, 184, and 215. Additionally, a selective polymerase chain reaction (PCR) for the multiple dideoxynucleoside resistance (MddNR) mutation Q151M was performed. RESULTS 16 patients (12%) harbored virus with one or more drug resistance mutations. The prevalence of patients with drug-resistant virus was 0% in 1992, 17% in 1993, 0% in 1994 (only 6 samples tested), 18% in 1995, 14% in 1996, and 9% in 1997. Mutation K70R (resistance to zidovudine) was found in 8 patients, M41L (resistance to zidovudine) in 5 patients, M184V/I (resistance to ddI/ddC/3TC) in 2 patients, and T215Y/F (resistance to zidovudine) in 4 patients. All samples were wild type at codons 69 (ddC), 74 (ddI), and 151 (MddNR). CONCLUSIONS Virus strains containing drug resistance mutations are now found in about 1 of 10 treatment-naive HIV-1-seropositive patients in Luxembourg. We believe that testing for drug-resistant virus before starting treatment should be recommended and will help to improve the selection of the most effective antiretroviral treatment. We also suggest the need for an international surveillance program on HIV drug resistance in treatment-naive patients.

UI MeSH Term Description Entries
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D008137 Longitudinal Studies Studies in which variables relating to an individual or group of individuals are assessed over a period of time. Bogalusa Heart Study,California Teachers Study,Framingham Heart Study,Jackson Heart Study,Longitudinal Survey,Tuskegee Syphilis Study,Bogalusa Heart Studies,California Teachers Studies,Framingham Heart Studies,Heart Studies, Bogalusa,Heart Studies, Framingham,Heart Studies, Jackson,Heart Study, Bogalusa,Heart Study, Framingham,Heart Study, Jackson,Jackson Heart Studies,Longitudinal Study,Longitudinal Surveys,Studies, Bogalusa Heart,Studies, California Teachers,Studies, Jackson Heart,Studies, Longitudinal,Study, Bogalusa Heart,Study, California Teachers,Study, Longitudinal,Survey, Longitudinal,Surveys, Longitudinal,Syphilis Studies, Tuskegee,Syphilis Study, Tuskegee,Teachers Studies, California,Teachers Study, California,Tuskegee Syphilis Studies
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D005814 Genes, Viral The functional hereditary units of VIRUSES. Viral Genes,Gene, Viral,Viral Gene
D005838 Genotype The genetic constitution of the individual, comprising the ALLELES present at each GENETIC LOCUS. Genogroup,Genogroups,Genotypes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D015331 Cohort Studies Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics. Birth Cohort Studies,Birth Cohort Study,Closed Cohort Studies,Cohort Analysis,Concurrent Studies,Historical Cohort Studies,Incidence Studies,Analysis, Cohort,Cohort Studies, Closed,Cohort Studies, Historical,Studies, Closed Cohort,Studies, Concurrent,Studies, Historical Cohort,Analyses, Cohort,Closed Cohort Study,Cohort Analyses,Cohort Studies, Birth,Cohort Study,Cohort Study, Birth,Cohort Study, Closed,Cohort Study, Historical,Concurrent Study,Historical Cohort Study,Incidence Study,Studies, Birth Cohort,Studies, Cohort,Studies, Incidence,Study, Birth Cohort,Study, Closed Cohort,Study, Cohort,Study, Concurrent,Study, Historical Cohort,Study, Incidence

Related Publications

E Fontaine, and C Lambert, and J Servais, and D Ninove, and J M Plesséria, and T Staub, and V Arendt, and P Kirpach, and I Robert, and F Schneider, and R Hemmer, and J C Schmit
Reverse transcriptase inhibitors drug resistance mutations in drug-naive HIV type 1 positive Kenyans.
January 2011, East African medical journal,
E Fontaine, and C Lambert, and J Servais, and D Ninove, and J M Plesséria, and T Staub, and V Arendt, and P Kirpach, and I Robert, and F Schneider, and R Hemmer, and J C Schmit
Identification of reverse transcriptase mutations associated with HIV-1 drug resistance mainly against non-nucleoside reverse transcriptase inhibitors in treatment-naive patients.
July 1999, AIDS (London, England),
E Fontaine, and C Lambert, and J Servais, and D Ninove, and J M Plesséria, and T Staub, and V Arendt, and P Kirpach, and I Robert, and F Schneider, and R Hemmer, and J C Schmit
Genotypic analysis methods for detection of drug resistance mutations in the HIV-1 proteinase and reverse transcriptase genes.
January 1999, Antiviral therapy,
E Fontaine, and C Lambert, and J Servais, and D Ninove, and J M Plesséria, and T Staub, and V Arendt, and P Kirpach, and I Robert, and F Schneider, and R Hemmer, and J C Schmit
Detection of low-frequency HIV type 1 reverse transcriptase drug resistance mutations by ultradeep sequencing in naive HIV type 1-infected individuals.
February 2014, AIDS research and human retroviruses,
E Fontaine, and C Lambert, and J Servais, and D Ninove, and J M Plesséria, and T Staub, and V Arendt, and P Kirpach, and I Robert, and F Schneider, and R Hemmer, and J C Schmit
Baseline E138 reverse transcriptase resistance-associated mutations in antiretroviral-naive HIV-infected patients.
June 2012, AIDS (London, England),
E Fontaine, and C Lambert, and J Servais, and D Ninove, and J M Plesséria, and T Staub, and V Arendt, and P Kirpach, and I Robert, and F Schneider, and R Hemmer, and J C Schmit
HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance.
January 2007, AIDS (London, England),
E Fontaine, and C Lambert, and J Servais, and D Ninove, and J M Plesséria, and T Staub, and V Arendt, and P Kirpach, and I Robert, and F Schneider, and R Hemmer, and J C Schmit
APOBEC3G versus reverse transcriptase in the generation of HIV-1 drug-resistance mutations.
September 2004, AIDS (London, England),
E Fontaine, and C Lambert, and J Servais, and D Ninove, and J M Plesséria, and T Staub, and V Arendt, and P Kirpach, and I Robert, and F Schneider, and R Hemmer, and J C Schmit
HIV-1 reverse transcriptase and protease mutations for drug-resistance detection among treatment-experienced and naïve HIV-infected individuals.
January 2020, PloS one,
E Fontaine, and C Lambert, and J Servais, and D Ninove, and J M Plesséria, and T Staub, and V Arendt, and P Kirpach, and I Robert, and F Schneider, and R Hemmer, and J C Schmit
Short communication: Drug resistance mutations in the HIV type 1 protease and reverse transcriptase genes in antiretroviral-naive Vietnamese children.
October 2012, AIDS research and human retroviruses,
E Fontaine, and C Lambert, and J Servais, and D Ninove, and J M Plesséria, and T Staub, and V Arendt, and P Kirpach, and I Robert, and F Schneider, and R Hemmer, and J C Schmit
Nucleoside drug resistance in HIV-1 reverse transcriptase.
March 1995, Nature structural biology,
Copied contents to your clipboard!